When Amgros is to estimate resource consumption, we ask relevant departments and hospital pharmacies to answer specific questions in relation to the use of the equal pharmaceuticals. This process helps ensure that the resource estimates reflect Danish clinical practice as well as possible. In order to ensure the best possible foundation for the assessment, Amgros also reviews any existing Danish literature and includes other relevant material. Suppliers are welcome to submit health economic analyses of current therapeutic areas to firstname.lastname@example.org.
When we have estimated resource consumption, we conduct a cost analysis. This enriches the expanded basis for comparison with unit costs for the resources included, as well as prices for the pharmaceuticals included. The pharmaceuticals prices we use in the cost analyses are list prices (purchase prices for pharmacies excl. VAT). We use the same framework for resource consumption and costs in the expanded basis for comparison as described in the Guidelines for cost analyses of new medicines and indications in the hospital sector.
The Medicines Council has to approve the expanded basis for comparison. After approval, the Council publishes it on its website. After this, Amgros uses the approved basis for comparison as the basis for the subsequent tendering procedure.
The final basis for comparison is the expanded basis for comparison in which we replace list prices with bid prices from the tendering round. The Danish Medicines Council prepares the pharmaceuticals recommendation using the final basis of comparison.
The pharmaceuticals recommendation is published on the Danish Medicines Council website.
We follow up on observance of pharmaceuticals recommendations by the Regions by preparing quarterly monitoring reports (in Danish).
We look at the costs of healthcare staff too
When Amgros is to assess which pharmaceutical is cheapest within the same therapeutic area, we take a holistic approach. This means that we not only look at pharmaceuticals prices themselves, but we also take into account the costs of actually using the drug
When the Danish Medicines Council is to assess several pharmaceuticals within the same therapeutic area, it prepares treatment guidelines.READ MORE
Is there is a reasonable relationship between the added clinical value from a new pharmaceutical compared with the existing treatment, and the costs this entails?READ MORE
Head of Business Intelligence and Health Economy
I’m responsible for operation and development of business intelligence and health economics. I make sure that our department can proudly claim to be the partner who gets things done.